Search Results - "Kazennyy, Boris Y"

Estimating the future burden of multidrug-resistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa: a mathematical modelling study by Sharma, Aditya, Dr, Hill, Andrew, PhD, Kurbatova, Ekaterina, MD, van der Walt, Martie, PhD, Kvasnovsky, Charlotte, MD, Tupasi, Thelma E, MD, Caoili, Janice C, MD, Gler, Maria Tarcela, MD, Volchenkov, Grigory V, MD, Kazennyy, Boris Y, MD, Demikhova, Olga V, MD, Bayona, Jaime, MD, Contreras, Carmen, BA, Yagui, Martin, MD, Leimane, Vaira, MD, Cho, Sang Nae, Prof, Kim, Hee Jin, MD, Kliiman, Kai, MD, Akksilp, Somsak, MD, Jou, Ruwen, PhD, Ershova, Julia, PhD, Dalton, Tracy, PhD, Cegielski, Peter, MD

“…Summary Background Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis are emerging worldwide. The Green Light Committee initiative…”
Get full text

Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study by Yuen, Courtney M, Kurbatova, Ekaterina V, Tupasi, Thelma, Caoili, Janice Campos, Van Der Walt, Martie, Kvasnovsky, Charlotte, Yagui, Martin, Bayona, Jaime, Contreras, Carmen, Leimane, Vaira, Ershova, Julia, Via, Laura E, Kim, HeeJin, Akksilp, Somsak, Kazennyy, Boris Y, Volchenkov, Grigory V, Jou, Ruwen, Kliiman, Kai, Demikhova, Olga V, Vasilyeva, Irina A, Dalton, Tracy, Cegielski, J Peter

“…For treating multidrug-resistant tuberculosis (MDR TB), the World Health Organization (WHO) recommends a regimen of at least four second-line drugs that are…”
Get full text

Additional drug resistance of multidrug-resistant tuberculosis in patients in 9 countries by Kurbatova, Ekaterina V, Dalton, Tracy, Ershova, Julia, Tupasi, Thelma, Caoili, Janice Campos, Van Der Walt, Martie, Kvasnovsky, Charlotte, Yagui, Martin, Bayona, Jaime, Contreras, Carmen, Leimane, Vaira, Via, Laura E, Kim, HeeJin, Akksilp, Somsak, Kazennyy, Boris Y, Volchenkov, Grigory V, Jou, Ruwen, Kliiman, Kai, Demikhova, Olga V, Cegielski, J Peter

“…Data from a large multicenter observational study of patients with multidrug-resistant tuberculosis (MDR TB) were analyzed to simulate the possible use of 2…”
Get full text

Extensive Drug Resistance Acquired During Treatment of Multidrug-Resistant Tuberculosis by Cegielski, J. Peter, Dalton, Tracy, Yagui, Martin, Wattanaamornkiet, Wanpen, Volchenkov, Grigory V., Via, Laura E., Van Der Walt, Martie, Tupasi, Thelma, Smith, Sarah E., Odendaal, Ronel, Leimane, Vaira, Kvasnovsky, Charlotte, Kuznetsova, Tatiana, Kurbatova, Ekaterina, Kummik, Tiina, Kuksa, Liga, Kliiman, Kai, Kiryanova, Elena V., Kim, HeeJin, Kim, Chang-ki, Kazennyy, Boris Y., Jou, Ruwen, Huang, Wei-Lun, Ershova, Julia, Erokhin, Vladislav V., Diem, Lois, Contreras, Carmen, Cho, Sang Nae, Chernousova, Larisa N., Chen, Michael P., Caoili, Janice Campos, Bayona, Jaime, Akksilp, Somsak

“…Background. Increasing access to drugs for the treatment of multidrug-resistant (MDR) tuberculosis is crucial but could lead to increasing resistance to these…”
Get full text

Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study by Dalton, Tracy, Dr, Cegielski, Peter, MD, Akksilp, Somsak, MD, Asencios, Luis, MPH, Caoili, Janice Campos, MD, Cho, Sang-Nae, Prof, Erokhin, Vladislav V, MD, Ershova, Julia, PhD, Gler, Ma Tarcela, MD, Kazennyy, Boris Y, MD, Kim, Hee Jin, MD, Kliiman, Kai, MD, Kurbatova, Ekaterina, MD, Kvasnovsky, Charlotte, MD, Leimane, Vaira, MD, van der Walt, Martie, PhD, Via, Laura E, PhD, Volchenkov, Grigory V, MD, Yagui, Martin A, MD, Kang, Hyungseok, MD

“…Summary Background The prevalence of extensively drug-resistant (XDR) tuberculosis is increasing due to the expanded use of second-line drugs in people with…”
Get full text

Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug Resistance by Cegielski, J. Peter, Kurbatova, Ekaterina, van der Walt, Martie, Brand, Jeannette, Ershova, Julia, Tupasi, Thelma, Caoili, Janice Campos, Dalton, Tracy, Contreras, Carmen, Yagui, Martin, Bayona, Jaime, Kvasnovsky, Charlotte, Leimane, Vaira, Kuksa, Liga, Chen, Michael P., Via, Laura E., Hwang, Soo Hee, Wolfgang, Melanie, Volchenkov, Grigory V., Somova, Tatiana, Smith, Sarah E., Akksilp, Somsak, Wattanaamornkiet, Wanpen, Kim, Hee Jin, Kim, Chang-ki, Kazennyy, Boris Y., Khorosheva, Tatiana, Kliiman, Kai, Viiklepp, Piret, Jou, Ruwen, Huang, Angela Song-En, Vasilyeva, Irina A., Demikhova, Olga V.

“…Background. Resistance to second-line drugs develops during treatment of multidrug-resistant (MDR) tuberculosis, but the impact on treatment outcome has not…”
Get full text

Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study: e1001932 by Yuen, Courtney M, Kurbatova, Ekaterina V, Tupasi, Thelma, Caoili, Janice Campos, Walt, Martie VanDer, Kvasnovsky, Charlotte, Yagui, Martin, Bayona, Jaime, Contreras, Carmen, Leimane, Vaira, Ershova, Julia, Via, Laura E, Kim, HeeJin, Akksilp, Somsak, Kazennyy, Boris Y, Volchenkov, Grigory V, Jou, Ruwen, Kliiman, Kai, Demikhova, Olga V, Vasilyeva, Irina A, Dalton, Tracy, Cegielski, J Peter

“…Background For treating multidrug-resistant tuberculosis (MDR TB), the World Health Organization (WHO) recommends a regimen of at least four second-line drugs…”
Get full text